The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers, MD, The Ohio State University, Columbus, OH, comments on two real-world studies that compared disease progression, using time to next treatment (TTNT), to assess the impact of dose adjustment of ibrutinib on clinical outcomes of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the first-line setting. A dose adjustment treatment strategy was not found to increase the risk of moving to the next line of treatment, meaning it is a feasible alternative to continuous standard dose treatment, allowing efficacy and safety to be balanced in patients who experience side effects. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo@Lilly, Pharmacyclics, AstraZeneca, Beigene, Janssen, Genentech, AbbVie; Research Funding: Novartis, Genentech, AbbVie.
